Overview

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Infections are common and associated with poor outcomes as well as high financial costs after kidney transplantation. Identifying and implementing strategies to reduce infections after kidney transplantation is important for improving patient outcomes. This study seeks to determine the feasibility of body surface area-based dosing of mycophenolate compared to standard dosing of mycophenolate in a pilot randomized controlled trial.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Mycophenolic Acid